Anavex Life Sciences Corp AVXL

Healthcare Biotechnology

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

NDAQ:AVXL - Post by User

Anavex Life Sciences Corp

Bullboard Posts

Post by R_J_on Mar 30, 2019 5:09am

52 Views

Post# 29557764

End of Month - March 2019

End of the Month (EOM) report for March 2019.
-
AVXL closed on 03/29/2019 at US$3.05
AVXL closed on 02/28/2019 at US$2.14
AVXL closed on 01/31/2019 at US$1.85
AVXL closed on 12/31/2018 at US$1.56
-
This is a 42.5%, a $O.91, gain for March.
This is a 95.5%, a $ 1.49, gain for the 1st Qtr of 2019.
-
S&P 500 Index, @ 2,834.4, gained 1.8% in March. [2.8% above its MA(200) @ 2,756.2]
The S&P is up 13.1%, or 237.5, for the 1st Qtr.
-
Two Hundred Day Moving Average [MA(200)] stuff.
AVXL's MA(200) ended March at $2.57
AVXL is now 18.7% above its MA(200).
-
Six News Releases on the AVXL Website in March
-
Use this link to see and read the all of March’s News Releases.
-
https://www.anavex.com/2019/03/
-
RJ

Bullboard Posts

Nvidia! Turnaround for Nel, Saturn Oil & Gas, Lufthansa, TUI?